Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452687 | 1.00 | RAB9A (0.52) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL29953440 | 0.90 | RAB9A (0.52) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL29953335 | 0.86 | NPC1 (0.53) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL29951720 | 0.85 | NPC1 (0.67) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL29956922 | 0.85 | NPC1 (0.52) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL12892596 | 0.84 | RAB9A (0.57) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL285633 | 0.84 | RAB9A (0.60) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL24890980 | 0.83 | NAAA (0.44) | RAB9ANPC1MAOBHRH3 | |
| SCHEMBL15330140 | 0.83 | NPC1 (0.53) | RAB9ANPC1MGLLMAOBCASP3 | |
| SCHEMBL5716053 | 0.83 | RAB9A (0.63) | RAB9ANPC1MGLLMAOBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | RAB9A 1980/4885NPC1 3502/4885MGLL 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.